# BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

Study · id `cardio:ct-nct03991442` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03991442](<https://clinicaltrials.gov/study/NCT03991442>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03991442

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

## Technical summary

Registry record NCT03991442. Randomized; triple masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2021-03-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 257 participants (enrolled count; ClinicalTrials.gov record NCT03991442, source copy `cardio:ctgov-nct03991442-2021-07-30`, retrieved 2026-10-26)
- Started: 2019-06-17 (actual) (ClinicalTrials.gov record NCT03991442, source copy `cardio:ctgov-nct03991442-2021-07-30`, retrieved 2026-10-26)
- Primary completion: 2021-03-02 (actual) (ClinicalTrials.gov record NCT03991442, source copy `cardio:ctgov-nct03991442-2021-07-30`, retrieved 2026-10-26)
- Completion: 2021-03-02 (actual) (ClinicalTrials.gov record NCT03991442, source copy `cardio:ctgov-nct03991442-2021-07-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03991442, source copy `cardio:ctgov-nct03991442-2021-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03991442-2021-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
- Acronym: FINAL
- Condition: Essential Hypertension
- Intervention (Drug): Fimasartan/Amlodipine
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 0bea2090caa37c5e0c7c0f9c638509eb727c8f467bd8c77ea84e6b99f88c7a0c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
